Base Year
Historical Year
Forecast Year
Generic injectables are high-quality bioequivalent versions of expensive innovator injectables, typically marketed at a lower price. These pharmaceutical products are injected either by a healthcare worker or the patients themselves and are used in certain clinical settings such as cancer care, trauma, and surgery, due to their rapid onset of action and higher bioavailability. There is a growing focus on the development of novel formulations of these faster-acting generics in oncology and specialty therapeutic areas, which is influencing the global generic injectables market landscape. Further, several generic manufacturers are increasingly investing in expanding their generic injectable portfolio to meet the growing healthcare demand, which is expected to fuel the Middle East and Africa generic injectables market growth.
The Middle Eastern and African countries are heavily investing in the healthcare and pharmaceutical sectors which has substantially affected the market demand. Recent data reveals that the size of the pharmaceutical market in Saudi Arabia has witnessed a massive increase, with most of the national pharmaceutical industries focused on the production of generics. Additionally, local manufacturing of generic injectables was estimated to be 30% out of all dosage forms in the region. This growth of local generic pharmaceutical manufacturing capabilities and capacities, supported by both public and private investments, is projected to boost the Middle East and Africa generic injectables market share.
One of the major market trends is the rise in strategic partnerships between public and private bodies to address global health challenges. For instance, in March 2023 , multinational pharmaceutical company GlaxoSmithKline (GSK plc) issued voluntary licenses to three companies (Aurobindo Pharma, Cipla, and Viatris) to manufacture generic versions of its HIV preventive medicine (injectable drug cabotegravir). This deal is likely to expedite market penetration of this injectable in lower-income countries. Further, Indian drugmaker Cipla reported plans to manufacture the generic injection in South Africa. Moreover, GSK also announced a public-private partnership with the Medicines Patent Pool (a United Nations-backed healthcare organization) in July 2022, to accelerate access to new HIV therapies in poor countries, with the introduction of its generic injectables expected by 2026. Such licensing agreements indicate an emphasis on increasing access to cost-effective medications which is anticipated to elevate the market value in the forecast period.
Middle East and Africa Generic Injectables Market Size
Middle East and Africa Generic Injectables Market Analysis
Middle East and Africa Generic Injectables Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
The market attained a value of about USD 0.9 billion in 2023 driven by the growth in local generic manufacturing capabilities in the region.
The market is anticipated to grow at a CAGR of 7.80% during the forecast period of 2024-2032, likely to reach a market value of USD 1.9 billion by 2032.
The rising investment in healthcare infrastructure and the growing healthcare needs are fuelling the demand for the market.
One of the significant trends in the market is the increase in public-private partnerships to accelerate the availability of affordable generic injectables in low-income countries. In July 2022, GSK plc announced one such strategic partnership with the Medicines Patent Pool to accelerate access to new HIV therapies in poor countries, with the introduction of its generic injectables expected by 2026.
Based on the product type, the market is segmented into large molecule injectables and small molecule injectables.
Container types available in the market include vials, premix, prefilled syringes, and ampoules, among others.
Major applications include oncology, cardiovascular, CNS, infectious diseases, and autoimmune disorders, among others.
The market breakup by route of administration includes intravenous, intramuscular, and subcutaneous, among others.
Distribution channels of the market are hospitals and retail pharmacies, among others.
The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.
The key players in the market are Pfizer Inc., Baxter, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Viatris Inc., and Sanofi.
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Pricing Plans
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Why Choose Us
We ensure that you get unmatchable competitive advantage by providing detailed insights about the existing market scenario as well as the emerging and high growth markets.
Regions and Countries with the Highest Number of Returning Clients
85%
Projects delivered with customization
90%
Projects involving industry specific expertise
24x7
Analysts Support
500+
Corporates choose us as their preferred partner
Commitment to Excellence
Diverse Teams
Innovative Solutions
Client Centric Approach
Continuous Improvement
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-120-433-0800
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
